EP0466710A1 - [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates - Google Patents

[5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates

Info

Publication number
EP0466710A1
EP0466710A1 EP90904269A EP90904269A EP0466710A1 EP 0466710 A1 EP0466710 A1 EP 0466710A1 EP 90904269 A EP90904269 A EP 90904269A EP 90904269 A EP90904269 A EP 90904269A EP 0466710 A1 EP0466710 A1 EP 0466710A1
Authority
EP
European Patent Office
Prior art keywords
formula
4alkyl
hydrogen
aryl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP90904269A
Other languages
German (de)
French (fr)
Inventor
Alfons Herman Margaretha Raeymaekers
Eddy Jean Edgard Freyne
Gustaaf Maria Boeckx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP0466710A1 publication Critical patent/EP0466710A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the benzimidazole carbamates of the present invention differ therefrom by the fact that they contain a benzimidazole moiety which is invariably substituted in the 5(6) position with a benzisoxa-, benzisothia-, or indazol radical and in particular by their favourable anthelminthic spectrum.
  • the present invention is concerned with novel benzimidazole carbamates of formula
  • R! is hydrogen, C ⁇ _4_lkyl, halo, hydroxy or C ⁇ _4alkyloxy;
  • R ⁇ is Cj_ alkyl
  • X is O, S, SO, SO2 or NR3, said R ⁇ being hydrogen, C ⁇ alkyl, aryl or arylC ⁇ _4alkyl; wherein aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from C ⁇ alkyl, halo, hydroxy or C ⁇ alkoxy.
  • halo is generic to fluoro, chloro, bromo and iodo and the term "C ⁇ _4alkyl" is me.ant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, 1-methylethyl, 1,1-dimethylethyl, 2-methylpropyl, butyl and the like.
  • the compounds of formula (I) may occur in tautomeric forms which tautomeric forms are intended to be within the scope of the present invention.
  • Preferred compounds within the present invention are those compounds of formula (I) wherein R is hydrogen or halo; R ⁇ is C ⁇ _4»alkyl; and X is O,S or NR3, said R3 being hydrogen, C ⁇ _4alkyl or aryl.
  • Particularly preferred compounds within the present invention are those preferred compounds wherein R* is hydrogen or fluoro and/or R ⁇ is methyl or ethyl and/or X is O,S or NR3, wherein R ⁇ is hydrogen, methyl or phenyl.
  • More preferred compounds within the invention are those preferred compounds wherein R is hydrogen, R ⁇ is methyl and X is O or S.
  • the most preferred compounds of the invention are selected from the group consisting of methyl [5-(l ,2-benzisoxazol-3-yl)- lH-benzimidazol-2-yl]carbamate and the pharmaceutically acceptable acid addition or metal substitution salts thereof.
  • the acid addition and metal substitution salts as mentioned hereinabove comprise the therapeutically active, and in particular, pharmaceutically acceptable non-toxic acid addition and metal substitution salt forms which the compounds of formula (I) are able to form.
  • the acid addition salts can conveniently be obtained by treating the base form with appropriate acids such as, for example, inorganic acids, such as hydrohalic acid, e.g.
  • organic acids such as, for example, acetic, hydroxyacetic, propanoic, 2-
  • the metal substitution salts hereinabove are meant to comprise the therapeutically active non-toxic metal substitution salt forms or metal complexes which the compounds of formula (I) are able to form, the term metal also comprising ammonium.
  • the latter can conveniently be obtained by treating the compounds of formula (I) with appropriate inorganic bases or salts, for example, ammonia or bases derived from alkali or earth alkaline metals, e.g. alkali metal or earth alkaline metal oxides or hydroxides such as sodium hydroxide, calcium hydroxide, calcium oxide and the like.
  • the salt form can be converted by treatment with alkali into the free base form or with acid into the free acidic form.
  • the term salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
  • the compounds of formula (I) can generally be prepared by ring closure of .an appropriately substituted benzenediamine of formula (II) or an acid addition salt thereof, with an appropriate isourea or isothiourea derivative of formula (HI).
  • the cyclization of (II) with (IE) can conveniently be carried out by stirring the reactants in a suitable solvent preferably in the presence of an appropriate acid, either organic or inorganic.
  • Organic acids comprise, for example, carboxylic acids, e.g. formic, acetic or propionic acid. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction and most preferably the reaction is carried out at the reflux temperature of the reaction mixture. In certain instances it may be advantageous to carry out the reaction under pressure.
  • Suitable solvents comprise organic solvents such as, for example, lower alkanols, e.g. methanol, ethanol, 2-propanol and the like alcohols; aromatic hydrocarbons, e.g.
  • benzene methylbenzene and the like; halogenated hydrocarbons, e.g. trichloromethane, dichloromethane, trichloroethane, trichloro- ethylene, chlorobenzene and the like; ethers such as tetrahydrofuran; ketones such as 2-propanone, 3-methyl-2-butanone; esters such as ethyl acetate; nitriles, e.g. acetonitrile and the like; and other common polar aprotic solvents such as, N,N-dimethylformamide, N,N-dimethylacetamide and the like solvents. Mixtures of such solvents with water may also be employed, e.g. mixtures of water with lower alkanols.
  • Benzimidazole carbamates of formula (I) may also be prepared by reacting a benzenediamine of formula (II) or an acid addition salt thereof with a cyanocarbamate of formula (IV).
  • Said reaction may be effected according to art-known procedures as described, for example, in U.S. Pat. Nos. 3,682,952 and 3,969,526, by reacting a benzene- diamine of formula (II) or an acid addition or metal substitution salt thereof with a cyanocarbamate of formula (TV) in a suitable solvent such as, for example, water, a lower alkanol, e.g. methanol, eth.anol; a ketone, e.g. 2-propanone; a polar aprotic solvent, e.g.
  • a suitable solvent such as, for example, water, a lower alkanol, e.g. methanol, eth.anol; a ketone, e.g. 2-propanone; a polar aprotic solvent, e.g.
  • an acid such as, for example, a mineral acid, e.g. hydrochloric acid.
  • Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction, more in particular the reaction may be conducted between 30 and 100°C.
  • the benzimidazole carbamates of formula (I) may be prepared by reacting a benzenediamine of formula (II) with cyanogen bromide (VI) and reacting the thus obtained 2-aminobenzimidazole (VII) with an appropriate haloformate ester (V), e.g. chloroformate ester.
  • V haloformate ester
  • benzimidazole carbamates of formula (I) may alternatively be prepared under similar procedures as are described in the literature for the preparation of related benzimidazole carbamates starting from appropriately substituted benzenediamines. A number of such procedures are described, for example, in "The chemistry of Hetero- cyclic Compounds" Vol. 40, part 1, pages 1-60, J. Wiley & Sons, New York (1981) and the references and Patents cited therein.
  • reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art such as, for example, extractions, distillation, crystallization, trituration and chromatography.
  • the compounds of formula (I) may also be converted into each other following art-known functional group transformation procedures.
  • the compounds of formula (I), wherein X is S may be converted into the corresponding compounds of formula (I), wherein X is SO or SO2 by an appropriate oxidation reaction, e.g. by reacting the former compounds with a suitable oxidating agent such as, for example, sodium chlorate, potassium permanganate, potassium periodate, a peroxide, e.g. 3-chlorobenzenecarboperoxoic acid, hydrogen peroxide and the like in a suitable solvent such as, an ether, e.g. tetrahydrofuran, l,l'-oxybisethane, a hydro ⁇ carbon, e.g. benzene, a halogenated hydrocarbon, e.g.
  • a suitable oxidating agent such as, for example, sodium chlorate, potassium permanganate, potassium periodate, a peroxide, e.g. 3-chlorobenzenecarboperoxoic acid, hydrogen peroxide and the like in a suitable solvent such as
  • said oxidation reaction is preferably conducted at lower temperatures with approximately one equivalent of the oxidating agent, while were a sulfonyl is desired, said oxidation reaction may be conducted at room or at an elevated temperature with an excess of oxidating agent.
  • the intermediates of formula (II) can be prepared from the corresponding nitro- substituted intermediates (VIII) following art-known nitro-to-amine reduction procedures such as for example, catalytic hydrogenation in a suitable solvent e.g. methanol or ethanol, in the presence of hydrogen and an appropriate catalyst e.g. platinum-on- charcoal, palladium-on-charcoal, Raney nickel, and the like. In some cases it may be useful to add an appropriate catalyst poison such as thiophene to the reaction mixture.
  • said nitro group may also be reduced to an amino group by reaction with a reducting agent such as, for example, sodium sulf ⁇ de, sodium dithionate and the like.
  • Said reaction can be carried out by stirring the reactants in a suitable solvent such as for example, water, an alcohol e.g. methanol, ethanol or a mixture of such solvents.
  • the intermediates of formula (VIII), wherein X is S, said compounds being represented by formula (Vlll-a), can be prepared by reacting an appropriately substituted benzoyl of formula (IX) with sulfur and ammonia in a reaction-inert solvent such as, for example, an ether, e.g. l,l'-oxybismethane, 2-methoxyethanol and the like, optionally under pressure.
  • a reaction-inert solvent such as, for example, an ether, e.g. l,l'-oxybismethane, 2-methoxyethanol and the like, optionally under pressure.
  • Z represents an appropriate leaving group, such as, for example, halo, e.g. fluoro or chloro; or a nitro group.
  • the intermediates of formula (VIII), wherein X is NR ⁇ " a , with R ⁇ _a being hydrogen or Cj ⁇ alkyl, said intermediates being represented by formula (Vlll-b), can be obtained by reacting the benzoyl intermediate (IX) with an appropriate hydrazine derivative R ⁇ - a -NH-NH2 (X) or an acid addition salt thereof.
  • Said reaction can be carried out in a suitable reaction-inert solvent optionally in the presence of a suitable base.
  • suitable solvents are, for example, water, alkanols, e.g. methanol, ethanol, 1-butanol and the like.
  • Appropriate bases preferably are amines such as N,N-diethylethanamine, 4-ethylmorpholine, pyridine and the like.
  • the benzoyl intermediates of formula (IX) can also be treated with hydroxyl- amine or an appropriate hydrazine derivative R3-b- H-NH2 (XI) or an acid addition salt thereof to form an intermediate of formula (XII) wherein X is O or NR ⁇ -b, said X being represented by X*, with R ⁇ - being aryl or arylC ⁇ alkyl.
  • Said reaction can be carried out with or without a suitable reaction-inert solvent and optionally in the presence of a base.
  • Suitable solvents are, for example, water, alkanols, e.g. methanol, ethanol, 1-butanol and the like.
  • Appropriate bases preferably are amines, such as N,N-diethyl- ethanamine, 4-ethylmorpholine, pyridine and the like.
  • Said cyclization reaction may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent such as, for example, water, hydro ⁇ carbons, e.g., benzene, dichloromethane and the like; lower alkanols, e.g. methanol, ethanol and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide,
  • a suitable reaction-inert solvent such as, for example, water, hydro ⁇ carbons, e.g., benzene, dichloromethane and the like; lower alkanols, e.g. methanol, ethanol and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide,
  • Appropriate bases are for example, hydroxides, alkoxides or hydrides, e.g. sodium hydroxide, sodium methoxide, sodium hydride and the like bases.
  • the intermediates of formula (IX) can be obtained by an aromatic nucleophilic substitution reaction of the halo group of intermediate (XIII).
  • halo is generic to fluoro, chloro, bromo and iodo.
  • the nucleophilic substitution reaction can be carried out with ammonia in a reaction-inert solvent such as for example, a hydrocarbon, e.g. pentane, benzene; a halogenated hydrocarbon such as dichloromethane and the like; an alcohol, e.g. methanol, ethanol and the like; a dipolar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethyl- acetamide, dimethyl sulfoxide and the like.
  • a reaction-inert solvent such as for example, a hydrocarbon, e.g. pentane, benzene; a halogenated hydrocarbon such as dichloromethane and the like; an alcohol, e.g. methanol, ethanol and the like; a dipolar aprotic solvent, e.g. N,N-dimethylformamide
  • the intermediates of formula (XIII) can in turn be obtained by Friedel-Crafts acylation of a benzene of formula (XIV) with an acyl halide, a carboxylic acid or an anhydride of formula (XV).
  • Said Friedel-Crafts reaction can be carried out by stirring the reaction mixture optionally in the presence of a reaction-inert solvent and in the presence of a catalyst such as, for example, a Lewis acid, e.g. ferric chloride, ferric bromide, aluminum trichloride and the like.
  • Suitable solvents are, for example, hydrocarbons, e.g. pentane, hexane, nitrobenzene, dichloromethane, tetrachloromethane and the like.
  • the intermediates of formula (VIII) wherein X is O, said intermediates being represented by formula (Vlll-d), may also be prepared by cyclizing an activated oxime derivative of formula (XVI), wherein T is an acyl residue and more particularly is (C ⁇ _4alkyl or aryl)carbonyl, e.g. propionyl and the like; (Chalky 1 or aryl)oxycarbonyl, e.g. methoxycarbonyl and the like; (C ⁇ alkyl or aryl)sulfonyl, e.g. methanesulfonyl, benzenesulfonyl and the like; N-acylaminocarbonyl, e.g. trichloromethylcarrx>nylamino- carbonyl and the like.
  • T is an acyl residue and more particularly is (C ⁇ _4alkyl or aryl)carbonyl, e.g. propionyl and the like; (Ch
  • Said cyclization reaction of the activated oxime derivative of formula (XVI) may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent. In some instances however, it may be advantageous not to add a base to the reaction mixture and to remove the acid liberated during the reaction by distillation. Alternatively, said cyclization may also be effected by heating the oxime derivative (XVI) in vacuo without a solvent.
  • Appropriate bases are for example, alkali and earth alkaline metal carbonates, hydrogen carbonates and amines, e.g. sodium carbonate, potassium carbonate, sodium hydrogen carbonate, j ,N-diethylethanamine, pyridine and the like bases.
  • Suitable solvents for said cyclization are, for example, aromatic hydrocarbons, e.g. benzene, methylbenzene and the like; ethers, e.g. l,l'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide, £ N-dimethylacetamide and the like; halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane and the like solvents.
  • aromatic hydrocarbons e.g. benzene, methylbenzene and the like
  • ethers e.g. l,l'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like
  • dipolar aprotic solvents e.g. N,N-dimethylformamide, £ N-dimethylacet
  • intermediates of formula (II), wherein X is NR ⁇ and R ⁇ is hydrogen, Ci _4alkyl, aryl, or arylC ⁇ alkyl, said intermediates being represented by formula (II- a), may also be prepared by a series of conversions starting from an aniline of formula
  • the aniline (XVII) is treated with an alkali metal nitrite, e.g. sodium nitrite, in an aqueous acidic medium thus obtaining the corresponding M-nitroso compound (XVIII-a) or, in case R ⁇ is hydrogen, thus obtaining the diazonium salt (XVIII-b).
  • an alkali metal nitrite e.g. sodium nitrite
  • R 3_c has the same meaning as R 3 with the proviso that hydrogen is excluded and in formula (XVIH-b) A " represents the conjugated base of the acid of the aqueous acidic medium mentioned hereinabove.
  • the N-nitroso compound (XVIII-a) or the diazonium salt (XVIH-b) is treated with an appropriate reducing agent such as, for example, hydrogen in the presence of a hydrogenation metal catalyst, e.g. Raney nickel or Raney cobalt ; or a sulfite, e.g. sodium sulfite; thus yielding the corresponding hydrazine derivative of formula (XIX), which in most instances spontaneously, or if necessary upon increasing the temperature, will cyclize to a compound of formula (Il-a).
  • a hydrogenation metal catalyst e.g. Raney nickel or Raney cobalt
  • a sulfite e.g. sodium sulfite
  • (XVII), (XVIII) and (XIX) P represents a suitable protective group which preferably is readily removable by hydrogenation such as, phenylmethyl and the like.
  • a suitable protective group which preferably is readily removable by hydrogenation such as, phenylmethyl and the like.
  • the unprotected intermediate (XLX) is obtained.
  • K-protected derivatives of formula (XIX) are obtained which may be deprotected, or may be converted as such to the H-protected intermediate (Il-a), which is afterwards deprotected.
  • the isourea or isothiourea derivatives of formula (HI) may be prepared by the reaction of an iso(thio)urea of formula (XX) or an acid addition salt thereof with an appropriate haloformate ester (V), e.g. chloroformate ester, in the presence of a base, as illustrated in the following scheme; with Y and R ⁇ being as defined hereinabove.
  • V haloformate ester
  • Suitable bases for the purpose of this procedure include metal alkoxides, metal hydroxides, alkali or earth alkali metal carbonates, hydrogen carbonates or organic bases, e.g. sodium methoxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, M > -diethylethanamine and the like.
  • the compounds of formula (I) and some of the intermediates in this invention may have an asymmetric carbon atom in their structure, e.g. when R ⁇ is a branched alkyl. This chiral center may be present in a R- and a S-configuration, this
  • Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids, or the like methods.
  • Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
  • the compounds of formula (I), the pharmaceutically acceptable acid-addition salts and stereochemically isomeric forms thereof have anthelminthic properties, in particular they posses a broad spectrum activity against parasites of warm blooded animals (human or animal), including both mature and immature parasitic forms, as represented for example by Nematodes, such as, Syngamus trachea in turkeys and pheasants, Ascaridia and Heterakis in chickens, Toxocara cati in cats, Ankylostoma tubaeforme in cats, Toxocara cams in dogs, Toxascaris leonin in dogs, Uncinaria stenocephala in dogs, Ankylostoma caninwn in dogs, Trichu ⁇ s vulpis in dogs, Trichinella spiralis in pigs and rats, Haemonchus contortus in sheep, Dictyocaulus filar ia in sheep and Trichostrongylides in sheep.
  • Nematodes such
  • Some compounds of the present invention are even found to be active against Cestodes, such as, Taenia pisiformis in dogs, Taenia hyda ⁇ gena in dogs, Taenia ovis in dogs, Dipylidium caninum in dogs, Taenia taeniaeformis in cats, Moniezia in sheep, Anitellina sp in sheep, Raillietina, Hydatigera taeniaformis and the like.
  • the compounds of the invention are found to exhibit high activity against various helminths infecting the intestinal tract of man and economically important animals, such as, sheep, cattle, horses, pigs and poultry, coupled with low systemic toxicity to the host.
  • the anthelminthic properties of compounds of formula (I) can be demonstrated for example in the "Taenia pisiformis in artificially infected dogs"-test and the "Heter ⁇ Ms g ⁇ llin ⁇ um in chicken”-test illustrating the useful anthelminthic properties of the compounds of the present invention.
  • the subject compounds may be formulated into various pharmaceutical forms for administration purposes.
  • an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier option comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as a pour-on, as an ointment.
  • Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
  • the compounds of formula (I) may also be added dissolved or suspended in drinking water.
  • the present invention provides anthelminthic compositions comprising an anthelminthically effective amount of an active compound of formula (I), either alone or in admixture with other active therapeutic ingredients such as, closantel, in admixture with suitable carriers.
  • the compounds of this invention constitute useful tools for the destroying or prevention of the growth of helminths and more particularly they can effectively be used in the treatment of subjects suffering from such helminths. Therefore the present invention provides a method of destroying or preventing the growth of helminths in warm blooded animals suffering from such helminths by administration of an anthelminthically effective amount of a compound of formula (I), a pharmaceutically acceptable acid addition salt or a possible stereochemically isomeric form thereof.
  • an effective amount would be from 1 to 100 mg/kg body weight, more particularly between 2.5 and 25 mg/kg body weight, preferably in a single administration.
  • Example 1 Preparation of the intermediates Example 1 a) To a stirred mixture of 465 parts of 1,3-difluorobenzene and 133.3 parts of aluminum trichloride was added dropwise a mixture of 110.1 parts of 4-chloro-3-nitro-benzoyl chloride and 116 parts of aluminum trichloride at 70°C. After stirring for 2 hours at reflux temperature, the reaction mixture was poured into ice-water. There were added 127 parts of hydrochloric acid and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was stirred in 2,2'-oxybis- propane.
  • Example 5 A mixture of 4 parts of intermediate 6, 2 parts of a solution of thiophene in methanol 4%, 119 parts of methanol and 89 parts of tetrahydrofuran was hydrogenated at 50°C and normal pressure with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was co-evaporated with methylbenzene, yielding 3.6 parts (99.9%) of 4-(l -phenyl- lH-indazol-3-yl)- 1,2- benzenediamine (interm. 13). In a similar manner there were also prepared :
  • Example 7 Taenia pisjformis in artificially infected dogs
  • Proglottids of Taenia pisiformis were collected from the faecal material of the infected dogs. After maceration and washing in tapewater the eggs were collected by passing the proglottids suspension through a sieve with aperture of 53 micron. The number of eggs was counted and about 1000 eggs were administered by gavage to young rabbits. After 5 weeks the rabbits had infectious Cvsticercus pisiformis in the peritoneal cavity. After autopsy of the rabbits the cysticerci were collected and administered orally in a gelatine capsule to young Beagle dags. The infective dose was about 15 cysticerci.
  • a hybrid line of 4 weeks old male Hisex chickens were infected orally with 600 Heterakis gallinae eggs.
  • the eggs were admixed in the normal chicken feed and administered for two consecutive days.
  • compound nos. 3 and 4 showed 100% after a single treatment 10 mg/kg.
  • compositions in dosage unit form suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.
  • Active ingredient as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.
  • Example 9 oral drops
  • Example 10 oral solution
  • Example 11 capsules
  • Example 12 film-coated tablets Preparation of tablet core
  • the wet powder mixture was sieved, dried and sieved again.
  • the whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient Coating
  • Example 13 iniectable solution 1.8 g methyl 4-hydroxybenzoate and 0.2 g propyl 4-hydroxybenzoate were dissolved in about 0.5 1 of boiling water for injection. After cooling to about 50°C there were added while stirring 4 g lactic acid, 0.05 g propylene glycol and 4 g of the AX. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 1 volume, giving a solution of 4 mg A.I. per ml. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Abstract

[5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1H-benzimidazol-a-yl] carbamates de formule (I) dans laquelle R1 représente hydrogène, alcoyle C1-4, halo, hydroxy ou alcoyloxy C1-4; R2 représente alcoyle C1-4; et X représente O, S, SO, SO2 ou NR3, ledit R3 représentant hydrogène, alcoyle C1-4, aryle ou arylalcoyle C1-4. Les composés de la formule (I) ont des propriétés anthelmintiques. Compositions contenant lesdits composés comme ingrédient actif, procédé de lutte contre les helminthes, et procédé de préparation desdits composés et desdites compositions.[5 (6) - (benzisoxa-, benzisothia- or indazol-3-yl) -1H-benzimidazol-a-yl] carbamates of formula (I) in which R1 represents hydrogen, C1-4 alkyl, halo, hydroxy or alkyloxy C1-4; R2 represents C1-4 alkyl; and X represents O, S, SO, SO2 or NR3, said R3 representing hydrogen, C1-4 alkyl, aryl or C1-4 arylalkyl. The compounds of formula (I) have anthelmintic properties. Compositions containing said compounds as an active ingredient, method of controlling helminths, and method of preparing said compounds and said compositions.

Description

[5(6)-(BENZISOXA-, BENZISOTHIA- OR INDAZOL-3-YL)-lH-BENZIMIDAZOL-2-
YLJCARBAMATES
Background of the invention
A large number of benzimidazole carbamates have been described as anthelminths. As most successful representatives there may be named mebendazole and flubendazole both described in U.S. Pat. No. 3,657,267, albendazole described in U.S. Pat. No. 3,915,986, oxibendazole described in U.S. Pat. No. 3,682,952 and fenbendazole described in U.S. Pat. No. 3,954,791.
The benzimidazole carbamates of the present invention differ therefrom by the fact that they contain a benzimidazole moiety which is invariably substituted in the 5(6) position with a benzisoxa-, benzisothia-, or indazol radical and in particular by their favourable anthelminthic spectrum.
Description of the invention
The present invention is concerned with novel benzimidazole carbamates of formula
(D
the acid addition or metal substitution salts thereof and the stereochemically isomeric forms thereof, wherein
R! is hydrogen, Cι_4_lkyl, halo, hydroxy or Cι_4alkyloxy;
R^ is Cj_ alkyl; and
X is O, S, SO, SO2 or NR3, said R^ being hydrogen, C^alkyl, aryl or arylCι_4alkyl; wherein aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from C^alkyl, halo, hydroxy or C^alkoxy.
As used in the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo and the term "Cι_4alkyl" is me.ant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, 1-methylethyl, 1,1-dimethylethyl, 2-methylpropyl, butyl and the like.
The compounds of formula (I) may occur in tautomeric forms which tautomeric forms are intended to be within the scope of the present invention.
Preferred compounds within the present invention are those compounds of formula (I) wherein R is hydrogen or halo; R^ is Cι_4»alkyl; and X is O,S or NR3, said R3 being hydrogen, Cι_4alkyl or aryl.
Particularly preferred compounds within the present invention are those preferred compounds wherein R* is hydrogen or fluoro and/or R^ is methyl or ethyl and/or X is O,S or NR3, wherein R^ is hydrogen, methyl or phenyl.
More preferred compounds within the invention are those preferred compounds wherein R is hydrogen, R^ is methyl and X is O or S.
The most preferred compounds of the invention are selected from the group consisting of methyl [5-(l ,2-benzisoxazol-3-yl)- lH-benzimidazol-2-yl]carbamate and the pharmaceutically acceptable acid addition or metal substitution salts thereof.
The acid addition and metal substitution salts as mentioned hereinabove comprise the therapeutically active, and in particular, pharmaceutically acceptable non-toxic acid addition and metal substitution salt forms which the compounds of formula (I) are able to form. The acid addition salts can conveniently be obtained by treating the base form with appropriate acids such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, hydroxyacetic, propanoic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-l,2,3-propanetricarboxylic, methanesulfonic, etlranesulfonic, benzene- sulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2- hydroxybenzoic and the like acids. The metal substitution salts hereinabove are meant to comprise the therapeutically active non-toxic metal substitution salt forms or metal complexes which the compounds of formula (I) are able to form, the term metal also comprising ammonium. The latter can conveniently be obtained by treating the compounds of formula (I) with appropriate inorganic bases or salts, for example, ammonia or bases derived from alkali or earth alkaline metals, e.g. alkali metal or earth alkaline metal oxides or hydroxides such as sodium hydroxide, calcium hydroxide, calcium oxide and the like. Conversely the salt form can be converted by treatment with alkali into the free base form or with acid into the free acidic form. The term salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
The compounds of formula (I) can generally be prepared by ring closure of .an appropriately substituted benzenediamine of formula (II) or an acid addition salt thereof, with an appropriate isourea or isothiourea derivative of formula (HI).
In the formulae (II) and (IE) the symbols X, R* and R^ have the same meaning as described for formula (I) hereinbefore, whereas Y is S or O and R^ is hydrogen or a radical of formula -COOR^.
Without being bound by any theory, it is assumed that the intermediates of formula (HI) may occur in tautomeric forms as tentatively illustrated in the following scheme.
Such tautomeric forms are naturally intended to be within the meaning of formula
(III).
The cyclization of (II) with (IE) can conveniently be carried out by stirring the reactants in a suitable solvent preferably in the presence of an appropriate acid, either organic or inorganic. Organic acids comprise, for example, carboxylic acids, e.g. formic, acetic or propionic acid. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction and most preferably the reaction is carried out at the reflux temperature of the reaction mixture. In certain instances it may be advantageous to carry out the reaction under pressure. Suitable solvents comprise organic solvents such as, for example, lower alkanols, e.g. methanol, ethanol, 2-propanol and the like alcohols; aromatic hydrocarbons, e.g. benzene, methylbenzene and the like; halogenated hydrocarbons, e.g. trichloromethane, dichloromethane, trichloroethane, trichloro- ethylene, chlorobenzene and the like; ethers such as tetrahydrofuran; ketones such as 2-propanone, 3-methyl-2-butanone; esters such as ethyl acetate; nitriles, e.g. acetonitrile and the like; and other common polar aprotic solvents such as, N,N-dimethylformamide, N,N-dimethylacetamide and the like solvents. Mixtures of such solvents with water may also be employed, e.g. mixtures of water with lower alkanols.
Benzimidazole carbamates of formula (I) may also be prepared by reacting a benzenediamine of formula (II) or an acid addition salt thereof with a cyanocarbamate of formula (IV).
(II) + NC-NH-COOR1 (TV) «- 0)
Said reaction may be effected according to art-known procedures as described, for example, in U.S. Pat. Nos. 3,682,952 and 3,969,526, by reacting a benzene- diamine of formula (II) or an acid addition or metal substitution salt thereof with a cyanocarbamate of formula (TV) in a suitable solvent such as, for example, water, a lower alkanol, e.g. methanol, eth.anol; a ketone, e.g. 2-propanone; a polar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, pyridine; or a mixture of such solvents, optionally in the presence of an acid such as, for example, a mineral acid, e.g. hydrochloric acid. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction, more in particular the reaction may be conducted between 30 and 100°C. In some instances it is appropriate to prepare the cyano- carbamate of formula (IV) in situ by reacting an appropriate halo formate ester (V), e.g. chloroformate ester with an aqueous solution of cyanamide or its calcium salt in the presence of an appropriate base such as, for example, an alkali metal carbonate or hydroxide. .
Alternatively, the benzimidazole carbamates of formula (I) may be prepared by reacting a benzenediamine of formula (II) with cyanogen bromide (VI) and reacting the thus obtained 2-aminobenzimidazole (VII) with an appropriate haloformate ester (V), e.g. chloroformate ester.
The benzimidazole carbamates of formula (I) may alternatively be prepared under similar procedures as are described in the literature for the preparation of related benzimidazole carbamates starting from appropriately substituted benzenediamines. A number of such procedures are described, for example, in "The chemistry of Hetero- cyclic Compounds" Vol. 40, part 1, pages 1-60, J. Wiley & Sons, New York (1981) and the references and Patents cited therein.
In all of the foregoing and in the following preparations, the reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art such as, for example, extractions, distillation, crystallization, trituration and chromatography.
The compounds of formula (I) may also be converted into each other following art-known functional group transformation procedures.
The compounds of formula (I), wherein X is S may be converted into the corresponding compounds of formula (I), wherein X is SO or SO2 by an appropriate oxidation reaction, e.g. by reacting the former compounds with a suitable oxidating agent such as, for example, sodium chlorate, potassium permanganate, potassium periodate, a peroxide, e.g. 3-chlorobenzenecarboperoxoic acid, hydrogen peroxide and the like in a suitable solvent such as, an ether, e.g. tetrahydrofuran, l,l'-oxybisethane, a hydro¬ carbon, e.g. benzene, a halogenated hydrocarbon, e.g. dichloromethane and the like. In the instance where a sulfoxide is desired, said oxidation reaction is preferably conducted at lower temperatures with approximately one equivalent of the oxidating agent, while were a sulfonyl is desired, said oxidation reaction may be conducted at room or at an elevated temperature with an excess of oxidating agent.
Some intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds and others are new. A number of such preparation methods will be described hereinafter in more detail.
The intermediates of formula (II) can be prepared from the corresponding nitro- substituted intermediates (VIII) following art-known nitro-to-amine reduction procedures such as for example, catalytic hydrogenation in a suitable solvent e.g. methanol or ethanol, in the presence of hydrogen and an appropriate catalyst e.g. platinum-on- charcoal, palladium-on-charcoal, Raney nickel, and the like. In some cases it may be useful to add an appropriate catalyst poison such as thiophene to the reaction mixture. Alternatively, said nitro group may also be reduced to an amino group by reaction with a reducting agent such as, for example, sodium sulfϊde, sodium dithionate and the like. Said reaction can be carried out by stirring the reactants in a suitable solvent such as for example, water, an alcohol e.g. methanol, ethanol or a mixture of such solvents.
The intermediates of formula (VIII), wherein X is S, said compounds being represented by formula (Vlll-a), can be prepared by reacting an appropriately substituted benzoyl of formula (IX) with sulfur and ammonia in a reaction-inert solvent such as, for example, an ether, e.g. l,l'-oxybismethane, 2-methoxyethanol and the like, optionally under pressure.
(K) (Vm-a) In formula (DC) Z represents an appropriate leaving group, such as, for example, halo, e.g. fluoro or chloro; or a nitro group.
The intermediates of formula (VIII), wherein X is NR^"a, with R^_a being hydrogen or Cj^alkyl, said intermediates being represented by formula (Vlll-b), can be obtained by reacting the benzoyl intermediate (IX) with an appropriate hydrazine derivative R^-a-NH-NH2 (X) or an acid addition salt thereof.
(IX) (Vffl-b)
Said reaction can be carried out in a suitable reaction-inert solvent optionally in the presence of a suitable base. Suitable solvents are, for example, water, alkanols, e.g. methanol, ethanol, 1-butanol and the like. Appropriate bases preferably are amines such as N,N-diethylethanamine, 4-ethylmorpholine, pyridine and the like.
The benzoyl intermediates of formula (IX) can also be treated with hydroxyl- amine or an appropriate hydrazine derivative R3-b- H-NH2 (XI) or an acid addition salt thereof to form an intermediate of formula (XII) wherein X is O or NR^-b, said X being represented by X*, with R^- being aryl or arylC^alkyl. Said reaction can be carried out with or without a suitable reaction-inert solvent and optionally in the presence of a base. Suitable solvents are, for example, water, alkanols, e.g. methanol, ethanol, 1-butanol and the like. Appropriate bases preferably are amines, such as N,N-diethyl- ethanamine, 4-ethylmorpholine, pyridine and the like.
The thus prepared intermediates of formula (XII) can readily be cyclized to obtain intermediates of formula (VIII), wherein X is O or NR^-b with R^-b being aryl or arylCι.4alkyl, said intermediates being represented by formula (VIII-c).
cyclization reaction
(xπ) (vm-c) Said cyclization reaction may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent such as, for example, water, hydro¬ carbons, e.g., benzene, dichloromethane and the like; lower alkanols, e.g. methanol, ethanol and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide,
H,M-dimethylacetamide, dimethyl sulfoxide and the like; or mixtures of said solvents. Appropriate bases are for example, hydroxides, alkoxides or hydrides, e.g. sodium hydroxide, sodium methoxide, sodium hydride and the like bases.
The intermediates of formula (IX) can be obtained by an aromatic nucleophilic substitution reaction of the halo group of intermediate (XIII).
(XIV) (XV) (Xm)
In the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo. The nucleophilic substitution reaction can be carried out with ammonia in a reaction-inert solvent such as for example, a hydrocarbon, e.g. pentane, benzene; a halogenated hydrocarbon such as dichloromethane and the like; an alcohol, e.g. methanol, ethanol and the like; a dipolar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethyl- acetamide, dimethyl sulfoxide and the like.
The intermediates of formula (XIII) can in turn be obtained by Friedel-Crafts acylation of a benzene of formula (XIV) with an acyl halide, a carboxylic acid or an anhydride of formula (XV). Said Friedel-Crafts reaction can be carried out by stirring the reaction mixture optionally in the presence of a reaction-inert solvent and in the presence of a catalyst such as, for example, a Lewis acid, e.g. ferric chloride, ferric bromide, aluminum trichloride and the like. Suitable solvents are, for example, hydrocarbons, e.g. pentane, hexane, nitrobenzene, dichloromethane, tetrachloromethane and the like.
The intermediates of formula (VIII) wherein X is O, said intermediates being represented by formula (Vlll-d), may also be prepared by cyclizing an activated oxime derivative of formula (XVI), wherein T is an acyl residue and more particularly is (Cι_4alkyl or aryl)carbonyl, e.g. propionyl and the like; (Chalky 1 or aryl)oxycarbonyl, e.g. methoxycarbonyl and the like; (C^alkyl or aryl)sulfonyl, e.g. methanesulfonyl, benzenesulfonyl and the like; N-acylaminocarbonyl, e.g. trichloromethylcarrx>nylamino- carbonyl and the like.
Said cyclization reaction of the activated oxime derivative of formula (XVI) may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent. In some instances however, it may be advantageous not to add a base to the reaction mixture and to remove the acid liberated during the reaction by distillation. Alternatively, said cyclization may also be effected by heating the oxime derivative (XVI) in vacuo without a solvent. Appropriate bases are for example, alkali and earth alkaline metal carbonates, hydrogen carbonates and amines, e.g. sodium carbonate, potassium carbonate, sodium hydrogen carbonate, j ,N-diethylethanamine, pyridine and the like bases. Suitable solvents for said cyclization are, for example, aromatic hydrocarbons, e.g. benzene, methylbenzene and the like; ethers, e.g. l,l'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide, £ N-dimethylacetamide and the like; halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane and the like solvents.
The intermediates of formula (II), wherein X is NR^ and R^ is hydrogen, Ci _4alkyl, aryl, or arylC^alkyl, said intermediates being represented by formula (II- a), may also be prepared by a series of conversions starting from an aniline of formula
Preferably, the aniline (XVII) is treated with an alkali metal nitrite, e.g. sodium nitrite, in an aqueous acidic medium thus obtaining the corresponding M-nitroso compound (XVIII-a) or, in case R^ is hydrogen, thus obtaining the diazonium salt (XVIII-b).
In formula (XVlU-a) R3_c has the same meaning as R3 with the proviso that hydrogen is excluded and in formula (XVIH-b) A" represents the conjugated base of the acid of the aqueous acidic medium mentioned hereinabove. The N-nitroso compound (XVIII-a) or the diazonium salt (XVIH-b) is treated with an appropriate reducing agent such as, for example, hydrogen in the presence of a hydrogenation metal catalyst, e.g. Raney nickel or Raney cobalt ; or a sulfite, e.g. sodium sulfite; thus yielding the corresponding hydrazine derivative of formula (XIX), which in most instances spontaneously, or if necessary upon increasing the temperature, will cyclize to a compound of formula (Il-a).
In the formulae (XVII), (XVIII) and (XIX) P represents a suitable protective group which preferably is readily removable by hydrogenation such as, phenylmethyl and the like. When using such protective group for the hydrogenation of (XVlU-a) or (XVIII-b), the unprotected intermediate (XLX) is obtained. In other instances, K-protected derivatives of formula (XIX) are obtained which may be deprotected, or may be converted as such to the H-protected intermediate (Il-a), which is afterwards deprotected.
The isourea or isothiourea derivatives of formula (HI) may be prepared by the reaction of an iso(thio)urea of formula (XX) or an acid addition salt thereof with an appropriate haloformate ester (V), e.g. chloroformate ester, in the presence of a base, as illustrated in the following scheme; with Y and R^ being as defined hereinabove.
Y-CH3
I base Y-CH3
HN=C-NH2 halo— COOR2 R4— NH-C=N-COOR2 (XX) (V) (in) Suitable bases for the purpose of this procedure include metal alkoxides, metal hydroxides, alkali or earth alkali metal carbonates, hydrogen carbonates or organic bases, e.g. sodium methoxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, M> -diethylethanamine and the like.
In some instances the compounds of formula (I) and some of the intermediates in this invention may have an asymmetric carbon atom in their structure, e.g. when R^ is a branched alkyl. This chiral center may be present in a R- and a S-configuration, this
R- and S-notation being in correspondence with the rules described in J. Org. Chem., 3_5_, 2849-2867 (1970). These stereochemically isomeric forms of the compounds of formula (I) are naturally intended to be embraced within the scope of the invention.
Pure stereochemically isomeric forms of the compounds of this invention may be obtained by the application of art known procedures. Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids, or the like methods.
Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
The compounds of formula (I), the pharmaceutically acceptable acid-addition salts and stereochemically isomeric forms thereof have anthelminthic properties, in particular they posses a broad spectrum activity against parasites of warm blooded animals (human or animal), including both mature and immature parasitic forms, as represented for example by Nematodes, such as, Syngamus trachea in turkeys and pheasants, Ascaridia and Heterakis in chickens, Toxocara cati in cats, Ankylostoma tubaeforme in cats, Toxocara cams in dogs, Toxascaris leonin in dogs, Uncinaria stenocephala in dogs, Ankylostoma caninwn in dogs, Trichuήs vulpis in dogs, Trichinella spiralis in pigs and rats, Haemonchus contortus in sheep, Dictyocaulus filar ia in sheep and Trichostrongylides in sheep. Some compounds of the present invention are even found to be active against Cestodes, such as, Taenia pisiformis in dogs, Taenia hydaήgena in dogs, Taenia ovis in dogs, Dipylidium caninum in dogs, Taenia taeniaeformis in cats, Moniezia in sheep, Anitellina sp in sheep, Raillietina, Hydatigera taeniaformis and the like. In particular, the compounds of the invention are found to exhibit high activity against various helminths infecting the intestinal tract of man and economically important animals, such as, sheep, cattle, horses, pigs and poultry, coupled with low systemic toxicity to the host. The anthelminthic properties of compounds of formula (I) can be demonstrated for example in the "Taenia pisiformis in artificially infected dogs"-test and the "HeterαMs gαllinαήum in chicken"-test illustrating the useful anthelminthic properties of the compounds of the present invention.
In view of their useful anthelminthic properties the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier option^ly comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as a pour-on, as an ointment.
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
In the instance where economically important animals are raised in large numbers, particularly poultry and birds, it is advantageous to add the compounds of formula (I) directly to the feed, as such or in the form of a premix or concentrate. In addition, the compounds of formula (I) may also be administered dissolved or suspended in drinking water.
In view of the anthelminthic properties of the compounds of formula (I) it is evident that the present invention provides anthelminthic compositions comprising an anthelminthically effective amount of an active compound of formula (I), either alone or in admixture with other active therapeutic ingredients such as, closantel, in admixture with suitable carriers.
In view of their potent activity in combating helminths the compounds of this invention constitute useful tools for the destroying or prevention of the growth of helminths and more particularly they can effectively be used in the treatment of subjects suffering from such helminths. Therefore the present invention provides a method of destroying or preventing the growth of helminths in warm blooded animals suffering from such helminths by administration of an anthelminthically effective amount of a compound of formula (I), a pharmaceutically acceptable acid addition salt or a possible stereochemically isomeric form thereof.
Those of skill in treating warm blooded animals suffering from such parasites could easily determine the effective amount from the test results presented herein. In general it is contemplated that an effective amount would be from 1 to 100 mg/kg body weight, more particularly between 2.5 and 25 mg/kg body weight, preferably in a single administration.
The following examples are intended to illustrate and not to limit the scope of the present invention. Unless otherwise stated all parts therein by weight. Experimental Part
A. Preparation of the intermediates Example 1 a) To a stirred mixture of 465 parts of 1,3-difluorobenzene and 133.3 parts of aluminum trichloride was added dropwise a mixture of 110.1 parts of 4-chloro-3-nitro-benzoyl chloride and 116 parts of aluminum trichloride at 70°C. After stirring for 2 hours at reflux temperature, the reaction mixture was poured into ice-water. There were added 127 parts of hydrochloric acid and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was stirred in 2,2'-oxybis- propane. The product was filtered off and dried, yielding 130 parts (87.4%) of (4-chloro-3-nitrophenyl) (2,4-difluorophenyl)methanone; mp.90.5°C (interm. 1). b) A mixture of 30 parts of intermediate 1 and 165 pans of dimethyl sulfoxide was stined for 4 hours at room temperature and for 2 hours at 50°C while ammonia was bubbled through. The reaction mixture was poured into 600 parts of ice- water. The precipitate was filtered off and crystallized from acetic acid. The product was filtered off, washed with 2,2'-oxybispropane and dried, yielding 23.3 parts (83.7%) of (4-amino-3- nitrophenyl) (2,4-difluorophenyl)methanone (interm. 2). c) A mixture of 23.3 parts of intermediate 2, 29.2 parts of hydroxylamine monohydro- chloride and 196 parts of pyridine was stirred for 2 hours at reflux temperature. The reaction mixture was evaporated and the residue was stined in 250 ml HC15%. The product was extracted with a mixture of trichloromethane and methanol (9:1) The extract was dried, filtered and evaporated, yielding 24 parts (97.4%) of (E+Z) (4-amino-3- nitrophenyl) (2,4-difluorophenyl) methanone.oxime (interm. 3). d) To a stined mixture of 3.12 parts of a dispersion of sodium hydride in mineral oil (50%) and 47 was added dropwise a mixture of 24 parts of intermediate 3 and 94 parts of M-dimethylformamide at 25°C (cooling on ice). The whole was stined for 1 hour at room temperature and was then poured into ice- water. After acidifying with hydrochloric acid, the solid was filtered off, washed with water and stined in acetonitrile. The product was filtered off, washed with 2,2'-oxybis- propane and dried, yielding 17.7 pans (79.0%) of 4-(6-fluoro-l,2-benzisoxazol-3-yl)-2- nitrobenzenamine; mp.238.9°C (interm.4). In a similar manner there were also prepared : 4-(l,2-benzisoxazol-3-yl)-2-nitrobenzenamine (interm. 5) and 2-nitro-4-(l-phenyl-lH- indazol-3-yl)benzenamine (interm.6). Example 2
A mixture of 10.4 parts of (4-amino-3-nitrophenyl) (2-fluorophenyl)methanone, 14.03 parts of methylhydrazine and 79 parts of ethanol was stined for 40 hours at reflux temperature. After cooling, the precipitated product was filtered off, washed with 2,2' -oxybispropane and dried, yielding 5.5 parts (51.3%) of 4-(l -methyl- lH-indazol-3- yl)-2-nitrobenzenamine; mp. 230.6°C (interm. 7). In a similar manner there was also prepared : 4-(lH-indazol-3-yl)-2-nitrobenzenamine (interm. 8).
Example 3
A mixture of 10.4 parts of (4-amino-3-nitrophenyl) (2-fluorophenyl)methanone, 1.3 parts of sulfur, 40 parts of ammonia and 194 parts of 2-methoxyethanol was stined for 20 hours in an autoclave at 160°C. The reaction mixture was evaporated and the residue was stined in dichloromethane. The product was filtered off and dried, yielding 3.1 parts (28.6%) of 4-(l,2-benzisothiazol-3-yl)-2-nitrobenzenamine (interm. 9).
Example 4
A mixture of 7.65 parts of intermediate 5, 24.1 parts of sodium dithionate, 158 parts of ethanol and 100 parts of water was stined for 2 hours at room temperature and for 1 1/4 hours at reflux temperature. The solvent was evaporated and to the residue there were added water and sodium carbonate. The product was extracted with a mixture of trichloromethane and methanol (90:10). The extract was dried, filtered and evaporated, yielding 4.6 parts (68.1%) of 4-(l,2-benzisoxazol-3-yl)-l,2-benzenediamine (interm. 10). In a similar manner there were also prepared:
4-(6-fluoro-l,2-benzisoxazol-3-yl)-l,2-benzenediamine (interm. 11) and 4-(l,2-benzisothiazol-3-yl)-l,2-benzenediamine (interm. 12).
Example 5 A mixture of 4 parts of intermediate 6, 2 parts of a solution of thiophene in methanol 4%, 119 parts of methanol and 89 parts of tetrahydrofuran was hydrogenated at 50°C and normal pressure with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was co-evaporated with methylbenzene, yielding 3.6 parts (99.9%) of 4-(l -phenyl- lH-indazol-3-yl)- 1,2- benzenediamine (interm. 13). In a similar manner there were also prepared :
4-(l -methyl- lH-indazol-3-yl)-l,2-benzenediamine (interm. 14) and 4-(lH-indazol-3-yl)- 1,2-benzenediamine (interm. 15). B. Preparation of the final compounds Example 6
A mixture of 4.5 parts of intermediate 10, 6 parts of methyl (α-imino-α-methoxy- methyl)-carbamate, 4.4 parts of acetic acid and 298 parts of trichloromethane was stined and refluxed for 30 hours. The precipitated product was filtered off, washed succes¬ sively with methanol, water, methanol and 2,2'-oxybispropane and dried, yielding 4.5 parts (73.0%) of methyl [5-(l,2-benzisoxazol-3-yl)-lH-benzimidazol-2-yl]-carbamate; mp. >300°C (compound 1).
In a similar manner there were also prepared the compounds listed in Table 1. Table 1
Elementary analysis data (carbon, hydrogen, nitrogen)
C. Biological Examples
The strong anthelminthic activity of the compounds of formula (I) is clearly evidenced by the data obtained in the following experiments, which data are only given to illustrate the useful anthelminthic properties of all the compounds of formula (I) and not to limit the invention either with respect to the scope of susceptible parasites nor with respect to the scope of formula (I).
Example 7 : Taenia pisjformis in artificially infected dogs Proglottids of Taenia pisiformis were collected from the faecal material of the infected dogs. After maceration and washing in tapewater the eggs were collected by passing the proglottids suspension through a sieve with aperture of 53 micron. The number of eggs was counted and about 1000 eggs were administered by gavage to young rabbits. After 5 weeks the rabbits had infectious Cvsticercus pisiformis in the peritoneal cavity. After autopsy of the rabbits the cysticerci were collected and administered orally in a gelatine capsule to young Beagle dags. The infective dose was about 15 cysticerci.
Two months after the artificial infection the dogs were moved to isolated cages on wire floor to confirm the tapeworms infection by faecal examination. After a single treatment of these dogs with a compound of formula (I) the faecal material was collected every day for 4 days. Elimination of proglottids and scolices was recorded. Seven days after oral administration of a compound of formula (I) the dogs were autopsied and the efficacy of the compound was determined on the basis of the presence (or absence) of scolices in the intestine. For example, compound No. 1 showed 100% activity after a single treatment with 2.5 mg/kg.
Example 8 : Heterakis gallinarum in chickens
A hybrid line of 4 weeks old male Hisex chickens were infected orally with 600 Heterakis gallinae eggs. The eggs were admixed in the normal chicken feed and administered for two consecutive days.
Five weeks after infection they were treated orally with the test compound in a gelatin capsule at various dose levels. Each day after treatment and for 5 consecutive days the expelled nematodes were counted in the faeces. At the end of the experiment the animals were autopsied. The remaining nematodes were counted and identified. The percent efficacy is calculated, based on the ratio : number of expelled parasites x 100 number of expelled parasites + number of parasites at autopsy
For example, compound nos. 3 and 4 showed 100% after a single treatment 10 mg/kg.
D) CorηpQSitiQn Exam les
The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.
"Active ingredient" (AX) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.
Example 9 : oral drops
500 g of the A.I. was dissolved in 0.51 of 2-hydroxypropanoic acid and 1.5 1 of the polyethylene glycol at 60=80°C. After cooling to 30=40°C there were added 35 1 of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 g of sodium saccharin in 2.51 of purified water and while stirring there were added
2.5 1 of cocoa flavor and polyethylene glycol q.s. to a volume of 501, providing an oral drop solution comprising 10 mg of the A.I. (per ml). The resulting solution was filled into suitable containers.
Example 10 : oral solution
9 g of methyl 4-hydroxybenzoate and 1 part of propyl 4-hydroxybenzoate were dissolved in 41 of boiling purified water. In 31 of this solution were dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of the AX The latter solution was combined with the remaining part of the former solution and 121 1,2,3-propanetriol and 31 of sorbitol 70% solution were added thereto.40 g of sodium saccharin were dissolved in 0.51 of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 201 providing an oral solution comprising 5 mg of the A.I. per teaspoonful (5 ml). The resulting solution was filled in suitable containers.
Example 11 : capsules
20 g of the A.I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of the A.I.
Example 12 : film-coated tablets Preparation of tablet core
A mixture of 100 g of the A.I., 570 g lactose and 200 g starch was mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone (Kollidon-K 90®) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 g microcrystalline cellulose (Avicel®) and 15 g hydrogenated vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient Coating
To a solution of 10 g methyl cellulose (Methocel 60 HG®) in 75 ml of denaturated ethanol there was added a solution of 5 g of ethyl cellulose (Ethocel 22 cps ®) in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpynolidone and 30 ml of concentrated colour suspension (Opaspray K- 1-2109®) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.
Example 13 : iniectable solution 1.8 g methyl 4-hydroxybenzoate and 0.2 g propyl 4-hydroxybenzoate were dissolved in about 0.5 1 of boiling water for injection. After cooling to about 50°C there were added while stirring 4 g lactic acid, 0.05 g propylene glycol and 4 g of the AX.The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 1 volume, giving a solution of 4 mg A.I. per ml. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.
E ample 14 ; suppositories
3 g A.I. was dissolved in a solution of 3 g 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 g surfactant (SPAN®) and triglycerides (Witepsol 555®) q.s. ad 300 g were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38°C to form 100 suppositories each containing 30 mg of the active ingredient.

Claims

αAIMS
1. A chemical compound of formula
an acid addition or a metal substitution salt thereof, or a stereochemically isomeric form thereof, wherein
R! is hydrogen, Cj^aUcyl, halo, hydroxy or Cι_4alkyloxy; R2 is Cι _4alkyl; and
X is O, S, SO, SO2 or NR3, said R3 being hydrogen, Ci^alkyl, aryl or arylCι_4alkyl; wherein aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from Cj^alkyl, halo, hydroxy or C^alkoxy.
2. A chemical compound according to claim 1 wherein R* is hydrogen or halo; R2 is Cι_4alkyl; and X is O, S or NR3, said R^ being hydrogen, C^alkyl or aryl.
3. A chemical compound according to claim 2 wherein R is hydrogen or fluoro; R2 is methyl or ethyl .and X is O, S, NR^, sa_d R^ being hydrogen, methyl or phenyl.
4. A chemical compound according to claim 3 wherein R is hydrogen, R2 is methyl and X is O or S.
5. A chemical compound according to claim 1 wherein the compound is methyl [5-( 1 ,2-benzisoxazol-3-yl)- lH-benzimidazol-2-yl]carbamate.
6. An anthelminthic composition comprising a pharmaceutical carrier and as active ingredient an anthelminthic effective amount of at least one compound as claimed in any of claims 1-5.
7. A process for preparing a composition as claimed in claim 6 characterized in that the carrier is intimately mixed with the active ingredient.
8. A method of destroying or preventing the growth of helminths in warm-blooded animals suffering from such helminths by the administration of an anthelminthically effective amount of a compound as claimed in any of claims 1-5.
9. A chemical compound of formula
an acid addition salt thereof or a stereochemically isomeric form thereof, wherein R! is hydrogen, Cι_4alkyl, halo, hydroxy or Cι_4alkyloxy; and X is O, S, SO, SO2 or NR3, said R3 being hydrogen, Cι_4alkyl, aryl or arylCι_4alkyl; and aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from Cj.4alkyl, halo, hydroxy or Cι_4alkoxy.
10. A process for preparing a compound of formula
an acid addition or a metal substitution salt thereof, or a stereochemically isomeric form thereof, wherein
R! is hydrogen, Cι_4alkyl, halo, hydroxy or Cι_4alkyloxy;
R2 is Cι_4alkyl; and
X is O, S, SO, SO2 or NR3, said R3 being hydrogen, Cι_4alkyl, aryl or arylCι_4alkyl; wherein aryl is phenyl optionally substituted with 1 or 2 substitiuents each independently selected from Cι_4alkyl, halo, hydroxy or Cj^alkoxy,
characterized bv a) cyclizing a benzenediamine of formula
wherein X is O, S or NR3 with R^ being hydrogen, C]_4alkyl, aryl or arylCι_4alkyl, or an acid addition or metal substitution salt thereof, with an urea or isothiourea of formula
Y-CH3
R4— NH— C=N-COOR2 (JH)
wherein Y is S or O and R^ is hydrogen or a radical of formula -COOR2 with R2 having the same meaning as defined hereinbefore, in a reaction-inert solvent;
b) reacting a benzenedi-amine of formula
or an acid addition salt thereof, with a cyanocarbamate of formula
NC-NH-COOR1 (TV)
in a reaction-inert solvent;
c) reacting a benzenediamine of formula
03)
with cyanogen bromide, and reacting the thus obtained 2-aminobenzimidazole of formula
with an haloformate ester of formula halo-COOR* (V) in a reaction-inert solvent, or optionally converting the compounds of formula (I) into each other following art- known functional group transformation procedures, and, if desired, converting the compounds of formula (I) into a therapeutically active non-toxic acid-addition salt form by treatment with an appropriate acid or, conversely, converting the acid-addition or metal substitution salt into the free base form with alkali; and/or preparing stereochemically isomeric forms thereof.
11. A process for preparing a compound of formula (II) as defined in claim 9,
characterized by
a) reducing a nitrophenyl derivative of formula
b) cyclizing an intermediate of formula
(XIX) thus obtaining an intermediate of formula (H) wherein X is NR^ and R-* is hydrogen, C _4alkyl, aryl or arylCi _4alkyl, said intermediate being represented by formula
and optionally preparing salt forms or stereoisomers of the compounds of formula (II).
EP90904269A 1989-03-15 1990-03-07 [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates Pending EP0466710A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32427089A 1989-03-15 1989-03-15
US324270 1989-03-15

Publications (1)

Publication Number Publication Date
EP0466710A1 true EP0466710A1 (en) 1992-01-22

Family

ID=23262851

Family Applications (2)

Application Number Title Priority Date Filing Date
EP90200526A Ceased EP0387941A1 (en) 1989-03-15 1990-03-07 [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1H-benzimidazol-2-yl] carbamates
EP90904269A Pending EP0466710A1 (en) 1989-03-15 1990-03-07 [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP90200526A Ceased EP0387941A1 (en) 1989-03-15 1990-03-07 [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1H-benzimidazol-2-yl] carbamates

Country Status (12)

Country Link
EP (2) EP0387941A1 (en)
JP (1) JPH04504112A (en)
KR (1) KR920701199A (en)
CN (1) CN1045582A (en)
AU (1) AU630431B2 (en)
CA (1) CA2048629A1 (en)
IL (1) IL93719A0 (en)
NZ (1) NZ232785A (en)
PH (1) PH27055A (en)
PT (1) PT93426A (en)
ZA (1) ZA901957B (en)
ZW (1) ZW2890A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115273D0 (en) * 1991-07-15 1991-08-28 Pfizer Ltd Benzimidazole anthelmintics
GB9115272D0 (en) * 1991-07-15 1991-08-28 Pfizer Ltd Benzimidazole anthelmintics
GB9124002D0 (en) * 1991-11-12 1992-01-02 Pfizer Ltd Benzimidazole anthelmintic agents
GB9205368D0 (en) * 1992-03-12 1992-04-22 Pfizer Ltd Benzimidozole anthelmintic agents
AU2004268847A1 (en) 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
SG11201406730RA (en) * 2012-04-20 2014-11-27 Merial Ltd Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE599143A (en) * 1960-01-18
CH484194A (en) * 1964-11-03 1970-01-15 Commw Scient Ind Res Org Process for the preparation of chelates and their use as worm control agents
US3657267A (en) * 1969-06-20 1972-04-18 Janssen Pharmaceutica Nv Benzimidazole carbamates
BE793358A (en) * 1971-12-27 1973-06-27 Hoechst Ag NEW 2-CARBALCOXY-AMINO-BENZIMIDAZOLE DERIVATIVES PRESENTING ANTHELMINTIC ACTIVITY AND THEIR PREPARATION PROCESS
US3969526A (en) * 1973-05-29 1976-07-13 Smithkline Corporation Anthelmintic 5-heterocycliothio and oxy-2-carbalkoxyaminobenzimidazles
DE3905948A1 (en) * 1989-02-25 1990-08-30 Basf Ag SUBSTITUTED N-HYDROXYPYRAZOLES AND FUNGICIDES THAT CONTAIN THESE COMPOUNDS
RU1836357C (en) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Benzimidazole derivatives, their isomers, mixtures of isomers, hydrates or their physiologically bearable salts possessing properties antagonistic to angiotenzine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9010630A1 *

Also Published As

Publication number Publication date
NZ232785A (en) 1991-03-26
ZA901957B (en) 1991-11-27
EP0387941A1 (en) 1990-09-19
PH27055A (en) 1993-02-01
KR920701199A (en) 1992-08-11
CA2048629A1 (en) 1990-09-16
CN1045582A (en) 1990-09-26
PT93426A (en) 1990-11-07
ZW2890A1 (en) 1991-10-16
JPH04504112A (en) 1992-07-23
IL93719A0 (en) 1990-12-23
AU5178890A (en) 1990-10-09
AU630431B2 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
DE60007329T2 (en) N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS
EP0042593B1 (en) Aryloxy-propanol amines, process for their preparation and medicines containing these compounds
FR2643903A1 (en) NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
DE2905877A1 (en) NEW AMINOPROPANOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
FI71148B (en) PROCEDURE FOR FRAMSTATION OF ANTIHYPERTENSIVE 4H-1,2,4-TRIAZOLO (4,3-A) QUINOXALIN-4-ONER
US4826862A (en) Anthelminthic [(5(6) (1H-azole-1-ylmethyl)benzimidazole]carbamates
CA2733397A1 (en) Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof
KR940001729B1 (en) 2-phenylhexahydro-1,2,4-triazine-3,5 diones
EP0466710A1 (en) [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates
US3759938A (en) Thiazolidine derivatives
EP0374041B1 (en) Medicaments containing 2-benzothiazolamine derivatives, compounds and their preparation
US5256681A (en) [5(6)-(benzisoxa-,benzisothia-or indazol-3-yl)-1H-benzimidazol-2-yl]carbamates
WO1990010630A1 (en) [5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1h-benzimidazol-2-yl] carbamates
FR2802530A1 (en) NOVEL 3-AMINO-1-PHENYL-1H [1,2,4] TRIAZOLE BRANCHED SUBSTITUTED AMINO DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
SI9500053A (en) Fungicidal derivatives of 2-imidazoline-5-ones
PL101396B1 (en) METHOD OF PRODUCTION OF 2-CARBOALCOXYAMINOBENZIMIDAZOLYL-5/6 / -SULPHONIC ACID PHENYL ESTERS
EP0298921A1 (en) 1,2-Benzisoxazoles and 1,2-benzisothiazoles
FR2532310A1 (en) NOVEL BENZAMIDE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US4985427A (en) Triazine derivatives
CA1117114A (en) 3-sulphonyl-benzo-1,2,4-triazine and 3-sulphonyl-benzo-1,2,4-triazine 1-oxide compounds, their production and their medicinal use
EA006706B1 (en) Hiv inhibiting n-aminoimidazole derivatives
EP0402227A1 (en) 1-Phenyl-1,4-dihydro-3-amino-4-oxo-pyridazin derivatives, their preparation and their therapeutical application
US5180836A (en) Imidazole derivatives
SU1306474A3 (en) Method for producing 2-(2,4-difluorphenyl)-1,3-bis-(1h-1,2,4-triazole-1-yl)-propan-2-ol or pharmaceutically permissible salt thereof
US4303666A (en) 5-Phenylseleno-2-benzimidazole carbamates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19910805

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 90200526.3/0387941 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 25.05.92.

RTI1 Title (correction)

Free format text: ??5(6)-(BENZISOXA-, BENZISOTHIA- OR INDAZOL-3-YL)-1H-BENZIMIDAZOL-2-YL CARBAMATES